Business Plan

Fabry disease is a rare, X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene, which encodes the enzyme alpha-galactosidase A (alpha-Gal A). When alpha-Gal A activity is absent or severely reduced, a lipid substrate called globotriaosylceramide (Gb3) and its deacylated form (lyso-Gb3) accumulate progressively in the lysosomes of cells throughout the body. The consequence is a multi-system disease: patients develop chronic neuropathic pain beginning in childhood, progressive kidney dysfunction leading to renal failure in the third to fourth decade of life, hypertrophic cardiomyopathy and cardiac arrhythmias, and early stroke. Most patients also experience debilitating fatigue, gastrointestinal disturbance, and hearing loss. Life expectancy is reduced by approximately 15 to 20 years compared to the general population.

The disease affects all GLA variant types, though the clinical spectrum varies. Classic disease (near-zero enzyme activity) presents with the full multi-system burden described above. Patients with residual enzyme activity may present later but face the same progressive organ damage trajectory. Migalastat (Galafold), an oral pharmacological chaperone, is approved only for patients who carry an amenable GLA variant, which represents approximately 35 to 50% of the Fabry population. The remaining 50 to 65% have no oral option.

Prevalence estimates range from 1 in 40,000 to 1 in 117,000 live births, though the true prevalence is believed to be significantly higher due to diagnostic underrecognition, particularly in women. Approximately 5,000 to 10,000 patients are currently receiving enzyme replacement therapy (ERT) in the United States and Europe combined, representing a market generating over $1.5 billion annually for Sanofi (Fabrazyme) and Chiesi (Elfabrio) alone.

Current treatments for lysosomal storage disorders impose a severe and lifelong burden that is both clinical and personal. The problem operates on four dimensions:

These are not abstract clinical limitations. FACTS trial participants and others describe the burden in their own words:

Glafabra's Live-cel is a lentivirus-mediated gene therapy using the patient's own engineered cells to produce the missing enzyme internally. Patient cells are harvested, genetically engineered to express the corrected enzyme, and re-introduced into the patient. The modified cells distribute throughout the body, secrete the enzyme, and neighboring cells take it up to halt toxic metabolite accumulation.

Sangamo's AAV program (isaralgagene civaparvovec, ST-920) is under a rolling BLA submission and may become the first approved gene therapy for Fabry disease. This validates the curative gene therapy market for Fabry and demonstrates FDA's willingness to approve in this indication.

However, ST-920 has a structural limitation that Live-cel is specifically designed to address. AAV creates neutralizing antibodies, making re-administration impossible. When ST-920 expression wanes after 3–5 years, the patient has no path back to gene therapy through that program. A real patient (Timothy Holleran, 36 years old) enrolled in a 4DMT AAV trial at Emory University has already lost active gene expression after approximately two years and reached out to Glafabra directly, stating he "hated doing bi-weekly infusions" and hoping to qualify for gene therapy again. He is not amenable to migalastat. He represents the real patient that Live-cel's re-administrability advantage was designed for.

Orchard Therapeutics (now part of Kyowa Kirin) pioneered the same therapeutic modality as Live-cel: lentivirus-mediated hematopoietic stem cell gene correction for lysosomal storage disorders. The underlying science is closely related. The commercial and clinical difference lies entirely in the conditioning regimen required before cell infusion.

Orchard's OTL-203 program employs full myeloablative conditioning — a busulfan-based regimen equivalent in intensity to bone marrow transplant preparation. For Fabry disease, this is a disqualifying constraint. Fabry patients skew older and carry significant cardiac and renal comorbidities as a direct consequence of the disease itself. A large fraction of this population cannot safely tolerate myeloablative chemotherapy, which effectively caps the eligible patient pool at a small, healthier minority.

Live-cel substitutes reduced-intensity conditioning (RIC) using single-agent melphalan at non-myeloablative doses. The result: four of five FACTS trial patients received conditioning as an outpatient procedure and returned home the same day. This distinction is not incremental — it is the specific technical gap that ended AVROBIO's AVR-RD-01 program in 2022 and the gap that Live-cel was engineered to close. Where Orchard's platform reaches a conditioning-tolerant subset, Live-cel reaches the full Fabry patient population.

The FACTS trial (NCT02800070), led by co-founders Jeff Medin and Ronan Foley, followed 5 patients for 5 years (PMIDs 33633114, 39794302, 36816757).

AVROBIO's AVR-RD-01 used full myeloablative busulfan conditioning, restricting the eligible patient pool to those who can tolerate bone-marrow-transplant-level preparation. AVROBIO discontinued in 2022–2023; conditioning burden was central. Kathy Nicholls, one of Australia's leading Fabry specialists, summarized it precisely: "The tech actually worked but the conditioning changes killed it." The Live-cel program exists specifically to fix that.

Glafabra uses non-myeloablative reduced-intensity melphalan conditioning, delivered as an outpatient procedure for 4 of 5 FACTS patients. This distinction is clinically and commercially material: Live-cel broadens the eligible patient pool from the small subset who can tolerate myeloablation to the full Fabry patient population.

Our primary objective is to drive all assets to Phase 2 efficacy data to de-risk for acquisition. We are raising $16M ($1M Preseed SAFEs plus $15M Series A). Targeted acquisition of $1B to $5B by 2030 upon achievement of multi-indication Phase 2 data.

Glafabra has initiated structured engagement with select leading biopharmaceutical companies that hold existing commercial infrastructure in lysosomal storage disorders. Discussions are structured across co-development, licensing, and option-to-acquire frameworks, timed to coincide with key clinical de-risking milestones.

Glafabra is not just a Fabry company; it is a platform company solving the multi-billion-dollar problem of treatment tedium without the toxicity of conditioning-based gene therapies and without the dead end of non-repeatable AAV approaches.

Live-cel replaces 26 ERT infusions a year with a single re-administrable treatment that lasts at least five years, requires no myeloablative conditioning, and applies across hundreds of enzyme deficiency disorders. One FACTS patient forgot he had Fabry for four years. Another described gaining back all that time with his family. That is the clinical standard and the commercial story.

With Sangamo's ST-920 potentially becoming the first approved Fabry gene therapy, the urgency for a repeatable, variant-agnostic, non-AAV alternative has never been higher. When ST-920 expression wanes in treated patients, Live-cel is the only available follow-on. That pipeline of future patients represents a durable, expanding market that Glafabra uniquely occupies.

With multiple Tier-1 biopharmaceutical companies holding established commercial assets across the lysosomal storage disorder space and facing displacement from curative alternatives, the strategic urgency for a durable, full-population, repeatable cell-based platform has never been higher. Glafabra is positioned to be the inevitable successor to the current standard of care.